A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

• Japanese participants aged 6 to 17 years at screening

• Participants must have a weight of ≥ 15 kg

• Diagnosis of chronic plaque psoriasis for at least 3 months prior to screening

• Has moderate to severe plaque psoriasis at screening and baseline as defined by:

• PASI score ≥ 12; and

• BSA ≥ 10; and

• sPGA ≥ 3 (moderate to severe)

• Disease inadequately controlled by or contraindicated for ≥ 1 topical therapy forpsoriasis

• Candidate for systemic therapy or phototherapy

Exclusion Criteria:

• Psoriasis flare or rebound within 4 weeks prior to screening

• Evidence of skin conditions, other than psoriasis, that would interfere withclinical assessments

• Other than psoriasis, history of any clinically significant (as determined by theinvestigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic,renal, hematologic, immunologic disease, or other major uncontrolled disease

• Prior history of suicide attempt at any time in the participant's lifetime prior toscreening or baseline in the study, or major psychiatric illness requiringhospitalization within 3 years prior to signing the assent and informed consent

• Guttate, erythrodermic, or pustular psoriasis at screening and baseline